Conduit Pharmaceuticals Inc.

The momentum for this stock is not very good. Conduit Pharmaceuticals Inc. is not very popular among insiders. Tradey thinks it is not wise to invest in Conduit Pharmaceuticals Inc. .
Log in to see more information.
CDT Fundamental Data by TradingView

News

Why Is Conduit Pharmaceuticals (CDT) Stock Up 12% Today?
Why Is Conduit Pharmaceuticals (CDT) Stock Up 12% Today?

InvestorPlace InvestorPlace - Stock Market News, Stock Advice & Trading Tips\nConduit Pharmaceuticals stock is up on Wednesday alongside heavy trading following an invest update on CDT shares.\nThe post Why Is...\n more…

CDT Stock Earnings: Conduit Pharmaceuticals Reported Results for Q2 2024
CDT Stock Earnings: Conduit Pharmaceuticals Reported Results for Q2 2024

InvestorPlace InvestorPlace - Stock Market News, Stock Advice & Trading Tips\nConduit Pharmaceuticals just reported results for the second quarter of 2024.\nThe post CDT Stock Earnings: Conduit Pharmaceuticals...\n more…

Conduit Pharmaceuticals selects initial indicators for lead clinical candidate
Conduit Pharmaceuticals selects initial indicators for lead clinical candidate

The Fly See the rest of the story here.\n\nthefly.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fly's real-time, streaming news feed keeps individual...\n more…

Why Is Conduit Pharmaceuticals (CDT) Stock Up 123% Today?
Why Is Conduit Pharmaceuticals (CDT) Stock Up 123% Today?

InvestorPlace InvestorPlace - Stock Market News, Stock Advice & Trading Tips\nConduit Pharmaceuticals stock is up on Thursday with heavy trading of CDT shares after the company announce a new license agreement.\nThe...\n more…

EXCLUSIVE: Penny Stock Conduit Pharmaceuticals Inks Licensing Pact With AstraZeneca For Multiple Assets
EXCLUSIVE: Penny Stock Conduit Pharmaceuticals Inks Licensing Pact With AstraZeneca For Multiple Assets

Benzinga Conduit Pharmaceuticals has entered an exclusive licensing agreement with AstraZeneca to develop AZD1656, AZD5658, and AZD5904, targeting autoimmune disorders and idiopathic male infertility. Conduit plans Phase 2 trials for AZD1656 and AZD5658 in 2024.\n more…

Conduit Pharmaceuticals (NASDAQ:CDT) Stock Rating Upgraded by Berenberg Bank
Conduit Pharmaceuticals (NASDAQ:CDT) Stock Rating Upgraded by Berenberg Bank

Ticker Report Conduit Pharmaceuticals (NASDAQ:CDT - Get Free Report) was upgraded by analysts at Berenberg Bank to a "strong-buy" rating in a research report issued to clients and investors on Friday, Zacks.com...\n more…